Abbott India Limited 's Board of Directors, at its meeting held on May 11, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The results were prepared in accordance with Indian Accounting Standards (Ind AS) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and carry an unmodified audit opinion from statutory auditors M/s. Walker Chandiok & Co. LLP. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company intimated BSE Limited on May 13, 2026, that the audited financial results for the quarter and financial year ended March 31, 2026 were published in Business Standard (All Editions) and Loksatta (Mumbai) on Wednesday, May 13, 2026. The intimation was signed by Company Secretary Sangeeta Shetty (Membership No.: ACS 18865).

Financial Performance: FY26 vs FY25

Abbott India delivered a strong financial performance for the full year ended March 31, 2026. Revenue from operations grew to Rs. 6,929.05 crores from Rs. 6,409.15 crores in the previous year, while total income rose to Rs. 7,217.19 crores from Rs. 6,684.73 crores. Net profit for the year stood at Rs. 1,552.02 crores, compared to Rs. 1,414.44 crores in FY25. The following table summarises the key financial metrics:

Quarterly Performance: Q4 FY26

For the quarter ended March 31, 2026, Abbott India reported revenue from operations of Rs. 1,709.51 crores, compared to Rs. 1,604.59 crores in the corresponding quarter of the previous year. Profit before tax for the quarter stood at Rs. 531.23 crores versus Rs. 482.71 crores in Q4 FY25, while net profit came in at Rs. 394.93 crores against Rs. 367.04 crores. The basic/diluted earnings per share for the quarter was Rs. 185.85. On an operational efficiency basis, Q4 EBITDA stood at Rs. 4.8B versus Rs. 4.3B in the same quarter last year, with the EBITDA margin expanding to 28.09% from 26.73% year-on-year.

Dividend Declaration and Key Corporate Dates

The Board recommended a final dividend of Rs. 525 and a special dividend of Rs. 131 per equity share of Rs. 10 each for the financial year ended March 31, 2026, aggregating to Rs. 656 per share. This compares to a final dividend of Rs. 475 per equity share declared for the year ended March 31, 2025. The dividend is subject to approval by shareholders at the forthcoming Annual General Meeting. Key dates related to the dividend and AGM are as follows:

Balance Sheet and Cash Flow Highlights

As at March 31, 2026, Abbott India's total assets stood at Rs. 6,501.93 crores, up from Rs. 5,917.31 crores as at March 31, 2025. Total equity increased to Rs. 4,774.19 crores from Rs. 4,233.15 crores. Cash and cash equivalents at the end of FY26 were Rs. 442.33 crores, compared to Rs. 560.59 crores at the start of the year. Net cash flows generated from operating activities for FY26 amounted to Rs. 1,319.24 crores, against Rs. 1,011.84 crores in FY25.

Other Corporate Developments

The Board also approved the appointment of M/s. Kishore Bhatia & Associates, Cost Accountants (Firm Registration No. 00294), as Cost Auditors of the company for the financial year 2026-27, subject to ratification of remuneration by members at the Eighty-second AGM. Additionally, the company recognised an incremental cost of Rs. 18.10 crores as part of employee benefit expenses during FY26, following its assessment of the implications of the four New Labour Codes notified by the Government of India on November 21, 2025. The company operates in a single business segment — Pharmaceuticals. Mr. Munir Shaikh (DIN: 00096273), who was liable to retire by rotation at the forthcoming AGM, has not offered himself for re-appointment.

Abbott India Limited has issued a Postal Ballot Notice dated April 22, 2026, pursuant to Section 110 of the Companies Act, 2013, seeking shareholder approval for two board-level appointments. The notice was dispatched electronically on May 13, 2026, to members whose names appear in the Register of Members as on the Cut-Off Date of May 8, 2026. The resolutions will be transacted through remote e-voting, with KFin Technologies Limited (KFinTech) serving as the Registrar and Transfer Agent and e-voting service provider.

Proposed Board Appointments

The Postal Ballot Notice covers two resolutions for member consideration. The appointments were initially made by the Board of Directors on April 22, 2026, upon recommendation of the Nomination and Remuneration Committee, and now require formal shareholder ratification.

Profile of Mr. James Wenner

Mr. James Wenner (DIN: 11650998), aged 58 years, holds a degree in Accounting from Michigan State University and is a Certified Public Accountant. He currently serves as Vice President, Treasurer for Abbott Laboratories, USA, a role he was appointed to in November 2025. Prior to this, he served as Vice President, Internal Audit for Abbott Laboratories, USA. Mr. Wenner joined Abbott in 1994 as a Senior Auditor and has since held numerous finance leadership roles within the Nutrition and Diagnostics businesses. He is active in Abbott's Finance Development Committee and serves as Chairman of the Board for ALEC, the Abbott and AbbVie sponsored employee credit union. Before joining Abbott, he was a Certified Public Accountant with Deloitte. His appointment as a Non-Executive Director is subject to approval by an Ordinary Resolution. No remuneration is sought to be paid to Mr. Wenner in this capacity.

Profile of Mr. Neeraj Jain

Mr. Neeraj Jain (DIN: 00348591), aged 64 years, is a rank holder Chartered Accountant and Company Secretary with over 30 years of management experience in finance, supply chain and business across diversified industries. His appointment fills the vacancy created upon the completion of the second term of Ms. Anisha Motwani (DIN: 06943493) as Independent Director on April 24, 2026. Key areas of his expertise include:

• Strategic business partnering and process excellence
• Controllership, M&A, and business reorganization
• Talent development and compliance optimization

Mr. Jain began his career in management consulting at A F Ferguson, subsequently spending seventeen years with Hindustan Unilever (HUL), with his last role being General Manager, Commercial (Exports). He later joined Johnson & Johnson (J&J), where he served for thirteen years in senior leadership roles including Vice President Finance/Chief Financial Officer, and was a member of the India Management Board. Post his retirement from J&J in 2020, he co-founded Vinnies, an angel investment platform comprising approximately 150 CXOs, and serves as its founding director. He was recognized among the 100 most influential CFOs in India by CIMA in 2016 and by 9.9 Media in 2015. His appointment as Independent Director for 3 (three) consecutive years from April 25, 2026 requires approval by a Special Resolution.

Mr. Neeraj Jain — Board and Committee Positions (Other Entities)

E-Voting Schedule and Process

The remote e-voting facility is being provided through KFinTech's platform. Members whose names appear in the Register of Members as on the Cut-Off Date of May 8, 2026, are entitled to participate. The voting schedule is as follows:

The Scrutinizer for the Postal Ballot process is Mr. Taizoon Khumri (CP No. 88 and Membership No. FCS 993), failing him Mr. Husain Wagh (CP No. 12153 and Membership No. FCS 11268), failing him Ms. Fatema Fatehi (CP No. 18684 and Membership No. ACS 51448), partners of M/s. Khumri Wagh Fatehi & Associates LLP, Practicing Company Secretaries. If approved, the resolutions shall be deemed to have been passed on June 16, 2026, the last date of e-voting. Results will be published on the Company's website at www.abbott.co.in and on KFinTech's e-voting portal at https://evoting.kfintech.com , and communicated simultaneously to BSE Limited.